Assertio Holdings, Inc. (ASRT): Price to Sales

Corporate company logo of Assertio Holdings, Inc. (ASRT)

Assertio Holdings, Inc. (ASRT) generates revenue by optimizing established neurological brands, which yields short-term profits, although the business is limited by patent risks in the long term despite overall macro resilience. The revenue valuation illustrates this balance, where the parameter value equals 1.50. Price stability is supported by the absence of logistics chain disruptions and the clear capacity utilization of partner manufacturing facilities.

ASRT: Assertio Holdings P/S Multiple 07/04/2022 - 06/27/2026

Metric breakdowns and analytics for Assertio Holdings, Inc. (ASRT)

- price and consensus price forecast:
General company analysis:Assertio Holdings (ASRT)
Mass-produced product of assertiotx.com

The P/S ratio determines the market value of a business relative to its annual revenue, measuring the premium investors are willing to pay per unit of sales. For Assertio Holdings, Inc. (ASRT), the company's P/S level reflects the market valuation of its ability to maintain revenues amid generic expansion and pressure from insurers. The dynamics of this indicator allow for the verification of capitalization resilience against a reduction in the market share of its drugs. A decline in this metric may signal a reassessment of risks within the neurology sector.

Competing companies

Price-to-Revenue Coefficient biogen.com|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd (RGC) - Price to Sales|AXSM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|XENE: P/S Multiple|vikingtherapeutics.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Supernus|Price to Sales Catalyst Pharma CPRX|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Price-to-Revenue Ratio HRMY (Harmony Corp)|P/S Multiple BHVN (Biohaven Ltd.)|AMLX: Market Cap to Revenue Ratio|Trevi Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Praxis Precision Medicines Inc PRAX|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CBLL|PRTA (Prothena Biosciences) - P/S Multiple|ALEC - Price-to-Revenue Multiple|Price-to-Revenue Ratio Annexon (ANNX)|Price-to-Revenue Coefficient omeros.com|Neurogene Corp - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACIU|Voyager Therapeutics - P/S Multiple|Price-to-Revenue Coefficient neumoratx.com NMRA|Scilex (SCLX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TVGN|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue Cognition Therapeutics Inc. (CGTX)|Market Cap to Revenue IKT (Inhibikase Therapeutics)|Price-to-Revenue Coefficient cassavasciences.com|P/S Multiple COYA (Coya Therapeutics)|P/S Multiple VistaGen Therapeutics, Inc. VTGN|OVID - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Acumen Pharmaceuticals, Inc ABOS|CervoMed Inc. (CRVO) - Price-to-Revenue Ratio|Alterity Therapeutics Limited - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CLNN|PEPG (PepGen Corp) - Market Cap to Sales Volume|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|Relmada Corp - Market Cap to Revenue Ratio|P/S Multiple ANVS (Annovis Bio, Inc.)|Grace Therapeutics Inc (GRCE) - Price to Sales|AIFF: Market Cap to Revenue|KLTO - P/S Multiple|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|Reviva Pharmaceuticals, Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio MetaVia Inc.|Price to Sales neuraxis.com NRXS|P/S Multiple HSDT|P/S Multiple passagebio.com (PASG)|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|Price-to-Revenue Coefficient Minerva (NERV)|ATHA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient addextherapeutics.com ADXN|ALZN: P/S Multiple|Price to Sales Cyclerion Therapeutics, Inc. (CYCN)|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent, Inc.)|Market Cap to Sales Volume ATXI|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Price-to-Revenue Coefficient Cara Therapeutics Inc. (CARA)|CHRO - Price-to-Revenue Ratio|Price to Sales Eliem Therapeutics|ITCI (intracellulartherapies.com) - Market Cap to Revenue|longboardpharma.com - Market Capitalization-to-Revenue Ratio|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|NKGN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE - Price to Sales|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|trevena.com - Price-to-Revenue Ratio|Vigil Neuro - P/S Multiple|WENA (anewmeds.com) - Market Cap to Revenue Ratio|CERE: P/S Multiple